5 Best Under-the-Radar Stocks to Invest In

4. Exelixis, Inc. (NASDAQ:EXEL)

Number of Hedge Fund Holders: 41

On June 22, Exelixis, Inc. (NASDAQ:EXEL) reported final Phase 3 STELLAR 303 data, which showed zanzalintinib plus atezolizumab produced a non-statistically significant overall survival trend. It was in favor of the combination among metastatic colorectal cancer patients without active liver metastases. The company reported a median overall survival of 15.9 months for the combination as compared to 12.7 months for regorafenib. It also disclosed a hazard ratio of 0.83 and P = 0.1185, and no new safety signals emerged.

The oncology firm also said STELLAR 303 previously achieved its other dual primary endpoint by delivering a statistically significant survival benefit in the intention-to-treat population. Detailed findings were presented at the 2025 European Society for Medical Oncology Congress and published in The Lancet. The corporation noted the FDA accepted its New Drug Application for the combination in February 2026 and assigned a target action date of December 3, 2026.

Exelixis, Inc. (NASDAQ:EXEL) is an oncology company. Its products include cabometyx, cometriq, and cotellic.